Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 264

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 264
---
,830,913 $13.82 7.51$593 Vested and expected to vest as of December 31, 20244,950,016 $10.82 7.99$1,818 As of December 31, 2024, there was $9.9 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.8 years. No options were exercised during the year ended December 31, 2024. The total intrinsic value of the options exercised during the year ended December 31, 2023 was $0.2 million. As of December 31, 2024, 1,013,055 shares were reserved for issuance for new awards under the 2021 Plan. As of December 31, 2024, 110,000 shares were reserved for issuance for new awards under the 2023 Inducement Plan.

135

Restricted Stock UnitsRestricted stock consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU award is based on the Company’s stock price on the date of grant. Employee grants vest over four years. Forfeitures of RSUs are recognized as they occur. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. The total fair value of RSUs that vested  was $0.1 million for 2024. No RSUs vested in 2023.Activity with respect to the Company’s restricted stock units during the year ended December 31, 2024 is as follows:SharesWeighted AverageGrant Date Fair ValueNonvested shares at December 31, 202332,558 $4.30 Granted308,700 1.92 Vested/Issued(32,558)4.30 Forfeited(52,210)1.92 Nonvested shares at December 31, 2024256,490 $1.92 As of December 31, 2024, there was $0.4 million of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 3.2 years.Compensation Expense SummaryThe Company recognized the following compensation cost related to employee and non-employee share-based compensation activity for the periods presented (in thousands):